News

One approach to aligning cost/quality outcomes is Value-Based Benefit Design which is designed to lower out-of-pocket costs for high-value services while providing greater quality of life for members

According to several presenters at the recent America's Health Insurance Plans Institute, coordination, communication and challenges are now the industry's driving forces.

Clinician handwashing protocol varies widely. Standardized measures for monitoring handwashing are lacking and tracking costly hospital-acquired infections in relation to hand hygiene is spotty at best.

The changing market

The Commonwealth Fund supports research on practical healthcare issues to drive improvement, while also sharing data publicly. Lately, its task has been formidable.

Results of a new study presented at the American Society of Hypertension (ASH) annual meeting, found that the investigational triple combination therapy of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ), demonstrated significantly greater mean reductions in blood pressure as compared with corresponding dual combination therapy.

An experimental drug for hepatitis C from Vertex Pharmaceuticals, telaprevir, sharply increased the cure rate in a clinical trial, while reducing the time needed for treatment. Experts said the results could herald a new era in treating the sometimes-fatal disease that is often overlooked, as reported by The New York Times.

Most patients with resistant rheumatoid arthritis (RA) who failed to respond to an initial cycle of rituximab (Rituxan) showed clinical improvement following a second treatment cycle, a British study found, as reported by MedPage.

Most patients with resistant rheumatoid arthritis (RA) who failed to respond to an initial cycle of rituximab (Rituxan) showed clinical improvement following a second treatment cycle, a British study found, as reported by MedPage.

Researchers will explore whether a new, very low-cost, one-a-day combined ?polypill? could reduce the risk of heart attacks, strokes, and other cardiovascular problems across the world, in a major new international trial that has just launched, as reported by ScienceDaily.